Janssen recently initiated a Phase 1b/2 clinical development program to evaluate JNJ-68284528, a chimeric antigen receptor (CAR) T-cell therapy, as a possible treatment  of…
Myeloma
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Latest news
Two multi-year collaborative agreements were recently established by Amgen and the University of Texas MD Anderson Cancer Center to advance the development of…
Combining Aplidin (plitidepsin) with dexamethasone significantly extends their survival in heavily pretreated multiple myeloma patients compared to dexamethasone alone, data from a Phase 3 trial…
Most U.S. residents are unaware there are shortages in the availability of cancer drugs, such as those for multiple myeloma, a type of cancer…
A combination of Idera Pharmaceuticals’s treatment candidate tilsotolimod plus Yervoy (ipilimumab) is able to reduce tumors in a group of patients with refractory…
Adding Pomalyst (pomalidomide) to a combination of Velcade (bortezomib) and dexamethasone significantly extended…
